H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 31.75 DKK 2.75% Market Closed
Market Cap: 31.6B DKK

Relative Value

The Relative Value of one HLUN A stock under the Base Case scenario is 47.37 DKK. Compared to the current market price of 31.75 DKK, H Lundbeck A/S is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLUN A Relative Value
Base Case
47.37 DKK
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
47
vs Industry
61
Median 3Y
1.3
Median 5Y
1.3
Industry
2.5
Forward
1.3
vs History
47
vs Industry
38
Median 3Y
9.2
Median 5Y
9.2
Industry
21.5
vs History
2
vs Industry
39
Median 3Y
5.5
Median 5Y
5.5
Industry
16.6
vs History
42
vs Industry
36
Median 3Y
2.2
Median 5Y
2.2
Industry
24.9
vs History
65
vs Industry
53
Median 3Y
1.3
Median 5Y
1.3
Industry
2.1
vs History
10
vs Industry
50
Median 3Y
1.4
Median 5Y
1.4
Industry
2.7
Forward
1.8
vs History
10
vs Industry
65
Median 3Y
1.8
Median 5Y
1.8
Industry
5.2
vs History
21
vs Industry
40
Median 3Y
6
Median 5Y
6
Industry
12.8
Forward
6.9
vs History
28
vs Industry
37
Median 3Y
7.6
Median 5Y
7.6
Industry
16.3
vs History
0
vs Industry
31
Median 3Y
5.4
Median 5Y
5.4
Industry
14.9
vs History
2
vs Industry
25
Median 3Y
6.2
Median 5Y
6.2
Industry
17.9
vs History
65
vs Industry
60
Median 3Y
1
Median 5Y
1
Industry
1.9

Multiples Across Competitors

HLUN A Competitors Multiples
H Lundbeck A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
31.5B DKK 1.4 9.6 8.3 8.3
US
Eli Lilly and Co
NYSE:LLY
729.6B USD 14.9 65.7 35.3 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.2 20.8 14.4 16.5
CH
Roche Holding AG
SIX:ROG
213.3B CHF 3.5 25.8 9.7 11.3
CH
Novartis AG
SIX:NOVN
190.2B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
167.2B GBP 4.1 29.1 131.1 197.7
US
Merck & Co Inc
NYSE:MRK
198.7B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 2.1 16.8 7.3 10.3
P/E Multiple
Earnings Growth PEG
DK
H Lundbeck A/S
CSE:HLUN A
Average P/E: 23.8
9.6
21%
0.5
US
Eli Lilly and Co
NYSE:LLY
65.7
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBITDA: 395
8.3
4%
2.1
US
Eli Lilly and Co
NYSE:LLY
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.4
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 698.3
8.3
4%
2.1
US
Eli Lilly and Co
NYSE:LLY
38.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.7
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1